CDKN1A and thyroid cancer: In summary, our findings unveil p21 modulation, particularly through Nutlin 3A co-treatment, as a promising avenue for overcoming resistance in thyroid cancers, offering insights into novel therapeutic strategies to improve patient outcomes.